US Pharma MarketingAdCom expected for uniQure’s Huntington’s gene therapy, chief medical officer says
AdCom expected for uniQure’s Huntington’s gene therapy, chief medical officer says is a pharma and life sciences industry update from Pharmaceutical Technology. The story may affect commercial strategy, market access planning, stakeholder engagement, competitive positioning, and near-term monitoring for pharmaceutical and biotech teams.
If approved, uniQure’s AMT-130 would be the first disease-modifying treatment for the inherited neurodegenerative disorder.
Source: Pharmaceutical Technology